FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283713873> ?p ?o ?g. }

• W4283713873 endingPage "1861" @default.
• W4283713873 startingPage "1861.1" @default.
• W4283713873 abstract "Background A 50 years old woman, a medical doctor, came to our department with symmetrical proximal muscular weakness, several months after Covid-19 infection and three weeks after a second dose of Covid-19 mRNA vaccine. The patient had no prior or family history of autoimmune diseases and take no medicines. In the past she undergone an operation for double-kidney with frequent urinary infections. Objective findings have shown symmetrical proximal muscular weakness and classic sings of dermatomyositis - Gottron’s papules, shawl and holster signs, periungual vasculitis. Objectives We present a case of a 50 old woman with clinical and laboratory proven dermatomyositis, starting three weeks after a second dose of a Covid1-19 mRNA vaccine without other reasons. Methods The laboratory tests showed elevated CPK, lactate dehydrogenase, aspartate aminotransferase and alanine aminotransferase, high ANA – 1:1280 and myositis specific autoantibodies- anti-NXP2 and anti-Mi-2- beta. The electromyography showed myopathic changes and the muscle MRI – symmetrical edema of mm.obturator and mm.adductor brevis. We exclude diseases that may mimic inflammatory myopathies. We made a cancer screening – whole body MRI, colonoscopy, gastroscopy, mammography and gynecological exam, immunoblot for detection of paraneoplastic syndrome-associated neuronal antibodies, with no detection of cancer. Muscle biopsy of m.vastus lateralis showed attenuating muscle inflammation with advancing muscle atrophy and fibrosis. Results The diagnose dermatomyositis was made according Bohan and Peter criteria and we start a high dose (1mg/kg/day) glucocorticoid therapy with good initial clinical and laboratory effect. Two months after starting a therapy muscle weakness worsened together with difficulty of swallowing. We excluded steroid myopathy after second EMG and lack of improvement when tapering the GS dose. Methotrexate 20 mg/weekly was added as a steroid sparing drug with good response, but was stopped because flare of pyelonephritis. Accordning to the opinion of dermatologist hydroxychloroquine was started for a couple of weeks, because of active skin manifestations. Muscle weakness worsened on the background of treatment, which was stopped. We started a therapy with intravenous immunoglobulins and considered therapy with cyclophosphamide or azathioprine after urinary infection. Because the patient was infected for a second time with covid-19, although vaccine, we continued only with glucocorticoids and antiosteoporotic therapy. Conclusion The etiology and pathogenesis of inflammatory myopathies are not fully clarified so far. We speculate that the infection with Covid-19 as well as mRNA vaccine trigger inflammatory myopathy and compromise the patient’s immunity for poor treatment response with glucocorticoids and immunosuppressives. On the other hand advanced muscle atrophy and fibrosis within a short period show that suspected triggering factors could be a reason for difficult to treat such type of dermatomyiositis. Disclosure of Interests None declared" @default.
• W4283713873 created "2022-06-30" @default.
• W4283713873 creator A5035432925 @default.
• W4283713873 creator A5089217977 @default.
• W4283713873 date "2022-05-23" @default.
• W4283713873 modified "2023-09-25" @default.
• W4283713873 title "AB1518 CASE REPORT OF A HARD TO TREAT DERMATOMYOSITIS AFTER A COVID-19 INFECTION AND SUBSEQUENT VACCINATION" @default.
• W4283713873 doi "https://doi.org/10.1136/annrheumdis-2022-eular.3517" @default.
• W4283713873 hasPublicationYear "2022" @default.
• W4283713873 type Work @default.
• W4283713873 citedByCount "1" @default.
• W4283713873 countsByYear W42837138732022 @default.
• W4283713873 crossrefType "journal-article" @default.
• W4283713873 hasAuthorship W4283713873A5035432925 @default.
• W4283713873 hasAuthorship W4283713873A5089217977 @default.
• W4283713873 hasBestOaLocation W42837138731 @default.
• W4283713873 hasConcept C126322002 @default.
• W4283713873 hasConcept C142724271 @default.
• W4283713873 hasConcept C16005928 @default.
• W4283713873 hasConcept C2775934546 @default.
• W4283713873 hasConcept C2776418732 @default.
• W4283713873 hasConcept C2778751314 @default.
• W4283713873 hasConcept C2779123688 @default.
• W4283713873 hasConcept C2779134260 @default.
• W4283713873 hasConcept C2779999465 @default.
• W4283713873 hasConcept C2780181341 @default.
• W4283713873 hasConcept C2781232998 @default.
• W4283713873 hasConcept C3008058167 @default.
• W4283713873 hasConcept C524204448 @default.
• W4283713873 hasConcept C71924100 @default.
• W4283713873 hasConcept C90924648 @default.
• W4283713873 hasConceptScore W4283713873C126322002 @default.
• W4283713873 hasConceptScore W4283713873C142724271 @default.
• W4283713873 hasConceptScore W4283713873C16005928 @default.
• W4283713873 hasConceptScore W4283713873C2775934546 @default.
• W4283713873 hasConceptScore W4283713873C2776418732 @default.
• W4283713873 hasConceptScore W4283713873C2778751314 @default.
• W4283713873 hasConceptScore W4283713873C2779123688 @default.
• W4283713873 hasConceptScore W4283713873C2779134260 @default.
• W4283713873 hasConceptScore W4283713873C2779999465 @default.
• W4283713873 hasConceptScore W4283713873C2780181341 @default.
• W4283713873 hasConceptScore W4283713873C2781232998 @default.
• W4283713873 hasConceptScore W4283713873C3008058167 @default.
• W4283713873 hasConceptScore W4283713873C524204448 @default.
• W4283713873 hasConceptScore W4283713873C71924100 @default.
• W4283713873 hasConceptScore W4283713873C90924648 @default.
• W4283713873 hasIssue "Suppl 1" @default.
• W4283713873 hasLocation W42837138731 @default.
• W4283713873 hasOpenAccess W4283713873 @default.
• W4283713873 hasPrimaryLocation W42837138731 @default.
• W4283713873 hasRelatedWork W1911783194 @default.
• W4283713873 hasRelatedWork W1976912157 @default.
• W4283713873 hasRelatedWork W2049484723 @default.
• W4283713873 hasRelatedWork W2140227388 @default.
• W4283713873 hasRelatedWork W2969775412 @default.
• W4283713873 hasRelatedWork W2997974127 @default.
• W4283713873 hasRelatedWork W3044420079 @default.
• W4283713873 hasRelatedWork W4283713873 @default.
• W4283713873 hasRelatedWork W4297900568 @default.
• W4283713873 hasRelatedWork W4312784683 @default.
• W4283713873 hasVolume "81" @default.
• W4283713873 isParatext "false" @default.
• W4283713873 isRetracted "false" @default.
• W4283713873 workType "article" @default.